

Our research question was to investigate whether rheumatologists make different treatment choices in male and female patients, and whether male and female patients respond differently to the prescribed treatment.

MATERIALS AND METHODS

Data selection. Data were derived from the Measurement of Efficacy of Treatment in the Era of Outcome in Rheumatology (METEOR), an international observational register recording daily clinical practice. METEOR is not an inception cohort but includes data of all patients with RA visiting a rheumatologist. Data are entered through upload from existing electronic health record systems or registers or by using the free online METEOR tool. Because the register contains data collected in daily clinical practice, the number of visits and the frequency of followup visits differed among patients. At the first visit, several patient and disease characteristics are entered [e.g., year of birth, sex, rheumatoid factor (RF) and anticitrullinated protein antibodies (ACPA) status], and during followup visits, data on disease activity, medication, and physical functioning are gathered, all according to regular care. METEOR has been described extensively before¹³. Data in METEOR were gathered anonymously and recorded only daily clinical practice; hence, medical ethics committee approval was not required. To investigate the response to the first antirheumatic treatment [conventional synthetic disease-modifying antirheumatic drugs (csDMARD) and/or oral or parenteral glucocorticoids (GC)], we selected data of all patients who fulfilled the following criteria: symptom duration < 5 years, medication start within 3 months after diagnosis of RA according to the treating rheumatologist, baseline Disease Activity Score (DAS) ≥ 1.6 , available data regarding medication use at baseline and followup, and at least 1 visit with available composite disease activity measure (e.g., 28-joint DAS, Simplified Disease Activity Index, Clinical Disease Activity Index). All available followup visits were selected from the start until the first switch in antirheumatic medication, or until the end of followup. A medication switch was defined as either a change in type of drug [e.g., from methotrexate (MTX) to leflunomide] or the addition of a new drug (e.g., from MTX to MTX + prednisone), but does not include changes in the dose of the current medication or tapering of treatment (e.g., from combination therapy with MTX + prednisone to MTX monotherapy, or tapering to drug-free remission).

Outcome measures. Time to switch medication (i.e., the time to decide that the first antirheumatic treatment had failed), was used as an efficacy measure, which was compared between males and females.

Response to the first antirheumatic treatment was measured by the DAS¹⁴ and the Health Assessment Questionnaire (HAQ)¹⁵. Response to treatment was measured over time, taking all available visits into consideration.

Treatment groups. Initiated medications were first divided into 5 treatment groups: (1) csDMARD monotherapy; (2) csDMARD combination therapy; (3) a single csDMARD with a GC; (4) combination therapy with > 1 csDMARD and GC; and (5) GC monotherapy. Additional analyses were performed for individual medication combinations.

Statistical analyses. The proportion of patients starting the different medication strategies across sexes was compared at baseline. A Cox regression analysis was performed with the time to switch from the first to the second treatment strategy (as proxy for treatment failure) as outcome. Patients were censored when they switched treatment, or at the end of available followup. Sex was added as predictor and analyses were adjusted for potential confounders. We considered age, RF, ACPA, country, year of first visit, symptom duration at diagnosis, body mass index (BMI), smoking, and disease activity as potential confounders and performed linear regression analyses to assess whether these potential confounders were associated with the predictor sex. Each of these variables that was associated with sex ($p < 0.20$) was added as a confounder. Next, linear mixed model analyses were performed to assess whether men and women responded differently to treatment over time, as measured by DAS and HAQ. First, a general effect of sex on treatment response was calculated for all selected patients, by

adding sex, followup time, and the interaction between sex and followup time to the model. In the presence of a significant interaction ($p < 0.10$), analyses were stratified by sex. Subsequently, subgroup analyses were performed by treatment group and then by individual medication combinations, for medication combinations that were given to at least 100 patients. In these subgroups, the same analyses with the interaction term between followup time and sex were conducted. Analyses were adjusted for potential baseline confounders as described above, except for DAS, because this was the outcome of the analysis. To account for irregular time intervals, random intercept and random slope were added to each model, assuming an “exchangeable” covariance matrix.

Further, effect modification by country was tested by adding an interaction term between sex, time in followup, and country, and effect modification by age was tested by adding an interaction term between sex, time in followup, and dichotomized age (age < 50 and ≥ 50). If these interaction terms were nonsignificant, analyses were performed for all countries and both age categories together, and country and age were only added as potential confounders. P values < 0.05 were considered statistically significant.

Missing data regarding disease activity, HAQ, age, BMI, smoking, RF, and ACPA were imputed using additional information on sex, time in followup, country, medication, symptom duration, and year of first visit, using multivariable normal imputation (30 imputations)¹⁶. All analyses were performed using Stata SE version 14 (StataCorp LP).

RESULTS

Baseline characteristics and initial treatment. From the 36,576 patients included in the METEOR database, data of 5820 patients fulfilled the inclusion criteria of our current study (Supplementary Figure 1, available with the online version of this article). Of these, 1142 men and 4393 women fulfilled the selection criteria for available data and could thus be included in the current analyses. A flowchart of the selection process and a comparison of baseline characteristics of included and non-included patients are presented in Supplementary Figure 1 and Supplementary Table 1 (available with the online version of this article). Non-included patients had slightly longer symptom duration at diagnosis but were otherwise mostly similar to included patients. Baseline characteristics of the included patients are shown in Table 1. The median time (interquartile range; IQR) in followup was 15.3 months (IQR 8.1–31.3) for men and 15.3 months (IQR 6.7–35.7) for women, with a median of 4 visits (IQR 3–7) for both men and women. On average, women were slightly younger and slightly more often RF- and/or ACPA-positive, had longer symptom duration and higher disease activity compared to men, and fewer of them smoked compared to men. Initial medication for men and women is presented in Table 2.

In general, men and women were treated with similar strategies according to the 5 treatment groups. But across the treatment groups, women more often than men started a treatment strategy containing hydroxychloroquine [HCQ; HCQ monotherapy, MTX + HCQ, and HCQ + GC, but not MTX + sulfasalazine (SSZ) + HCQ]. Men more often started a treatment strategy containing SSZ and/or MTX (SSZ monotherapy, MTX + SSZ, and MTX + GC). Men who started HCQ monotherapy had on average a lower baseline

Table 1. Baseline characteristics of men and women. Mean (SD) reported unless otherwise specified.

Characteristics	Men, n = 1142 (21%)		Women, n = 4393 (79%)		p
	Values	N	Values	N	
Age at first visit, yrs	52.0 (14.9)	1139	46.9 (13.9)	4371	< 0.001
BMI, kg/m ²	27.1 (4.8)	730	27.0 (6.6)	2500	0.647
RF-positive, %	70.6	1104	75.5	4270	0.001
ACPA-positive, %	66.3	656	70.8	2363	< 0.001
Smoking, %		900		3832	< 0.001
Never	62.3		88.5		
Previous smoker	14.2		5.2		
Current smoker	23.0		6.3		
Symptom duration at diagnosis, mos, median (IQR)	10.3 (3.9–23.9)	1142	12.3 (5.9–34.8)	4393	< 0.001
Time to treatment initiation from diagnosis, days	4.3 (14.8)	1142	3.8 (14.0)	4393	0.009
HAQ, 0–3	0.96 (0.69)	897	1.1 (0.68)	3668	< 0.001
DAS	3.5 (1.1)	753	3.7 (1.0)	2689	< 0.001
DAS28	5.5 (1.4)	817	5.8 (1.4)	2933	< 0.001
ESR, mm/h	46.2 (32.2)	1017	57.4 (33.7)	3809	< 0.001
CRP, mg/l, median (IQR)	24 (11–50)	869	21 (9–45)	3391	< 0.001
VAS patient global, 0–100	53.5 (23.0)	896	55.0 (22.0)	3295	0.091
Ritchie articular index, 0–78	8.6 (6.4)	1061	10.2 (6.6)	4075	< 0.001
SJC, 0–44	7.2 (7.4)	1062	6.5 (6.5)	4079	0.027
TJC 28, 0–28	10.9 (8.7)	1129	12.6 (9.3)	4347	< 0.001
SJC 28, 0–28	6.4 (6.2)	1133	5.8 (5.5)	4368	0.021

BMI: body mass index; RF: rheumatoid factor; ACPA: anticitrullinated protein antibodies; IQR: interquartile range; HAQ: Health Assessment Questionnaire; DAS: Disease Activity Score; DAS28: 28-joint DAS; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; VAS: visual analog scale; SJC: swollen joint count; SJC28: 28-joint SJC; TJC28: 28-joint tender joint count.

DAS than men starting different treatments, as well as lower than women who started HCQ. Women who started MTX monotherapy on average had a slightly higher baseline DAS than women starting monotherapy with other csDMARD. In the group starting with combination therapy of > 1 csDMARD and a GC, no sex differences were present. In addition, because HCQ might be preferentially prescribed to pregnant women or to women with a desire to conceive, we assessed whether HCQ was more often prescribed to women of childbearing age. It was found that women \geq 50 years of age were less often prescribed HCQ (27.5% vs 36.8% for women < 50 yrs). However, the same was found for men (14.9% for men \geq 50 years vs 23.8% for men < 50 yrs).

Further, because medication use differed slightly among countries, initial treatment of men and women was shown per country, for countries contributing at least 100 patients (Supplementary Tables 2–9, available with the online version of this article). Specifically, in contrast to the overall findings, women compared to men did not receive more often HCQ monotherapy in Portugal or in the UK, not more often combination of MTX + HCQ in the UK, and not more often combination of HCQ + GC in Mexico or in the UK. Last, the proportion of patients receiving GC monotherapy differed for some countries, with more men in Mexico and Portugal and more women in the Netherlands receiving GC monotherapy.

Treatment switch. Time to switch medication (i.e., the time to decide that the first treatment step had failed) was shorter in women [median 175 (IQR 91–384) days or 25 (IQR 13–55) weeks, n = 2756] than in men [median 200 (IQR 98–400) days or 29 (IQR 14–57) weeks, n = 647]. In total, 2146 patients (1637 women, 495 men) did not switch treatment before the end of followup and were censored [median followup time 336 (IQR 132–708) days or 48 (IQR 19–101) weeks for women and 387 (IQR 187–733) days or 55 (IQR 27–105) weeks for men]. Cox regression analyses on the effect of sex on time from the initial treatment to a next treatment step confirmed that women were slightly more likely to switch treatment than men (HR 1.22, 95% CI 1.12–1.33). However, after adjusting for age, RF, ACPA, symptom duration at diagnosis, country, BMI, smoking (all at baseline), and DAS as time-varying covariate, the effect disappeared (HR 1.02, 95% CI 0.93–1.12).

Treatment response. Analyses on the effects of sex on treatment response revealed that for most treatment groups at baseline, women had a slightly higher DAS (β 0.18, 95% CI 0.13–0.24) and HAQ (β 0.16, 95% CI 0.12–0.19) for all treatment groups combined (Supplementary Table 10, available with the online version of this article). The interaction term between sex and time was statistically significant for the DAS outcome over time (p = 0.011). However, after

Table 2. Initial treatment of men and women.

Variables	Men, n = 1142		Women, n = 4393	
	n (%)	DAS*, mean (SD)	n (%)	DAS*, mean (SD)
csDMARD monotherapy	421 (36.9)	3.4 (1.1)	1804 (41.2)	3.6 (1.0)
MTX	248 (58.9)	3.6 (1.2)	983 (54.5)	3.8 (1.0)
SSZ	83 (19.7)	3.2 (1.1)	181 (10.0)	3.3 (0.9)
HCQ	80 (19.0)	2.8 (0.8)	597 (33.1)	3.4 (0.9)
Other	10 (2.4)	–	43 (2.4)	–
GC monotherapy	103 (9.0)	3.3 (0.9)	252 (5.7)	3.3 (0.9)
csDMARD combination therapy	233 (20.4)	3.5 (1.1)	947 (21.6)	3.9 (1.0)
MTX + HCQ	95 (40.8)	3.3 (1.0)	554 (57.9)	3.9 (1.0)
MTX + SSZ	70 (30.0)	3.6 (1.0)	192 (20.1)	3.7 (1.0)
MTX + SSZ + HCQ	40 (17.2)	3.1 (0.7)	122 (12.8)	3.5 (0.9)
SSZ + HCQ	19 (8.2)	3.3 (0.9)	48 (5.0)	3.5 (0.9)
MTX + LEF	5 (2.2)	4.8 (0.7)	24 (2.5)	3.8 (1.2)
Other	4 (1.7)	–	7 (0.7)	–
csDMARD + GC	271 (23.7)	3.7 (1.2)	928 (21.2)	3.6 (1.0)
MTX + GC	226 (83.4)	3.7 (1.1)	705 (76.0)	3.6 (1.0)
HCQ + GC	21 (7.8)	3.8 (1.7)	136 (14.8)	3.6 (0.9)
SSZ + GC	17 (6.3)	3.6 (1.3)	53 (5.7)	3.8 (1.0)
LEF + GC	4 (1.5)	3.8 (1.2)	26 (2.8)	3.4 (1.1)
Other	3 (1.1)	–	8 (0.9)	–
Combination csDMARD + GC	114 (10.0)	3.6 (1.1)	452 (10.3)	3.9 (1.0)
MTX + HCQ + GC	48 (42.1)	3.5 (1.2)	205 (45.4)	3.8 (1.0)
MTX + SSZ + GC	26 (22.8)	3.6 (0.9)	111 (24.6)	3.9 (1.0)
MTX + SSZ + HCQ + GC	20 (17.5)	3.4 (0.8)	74 (16.4)	3.6 (1.0)
SSZ + HCQ + GC	13 (11.4)	3.4 (0.9)	32 (7.1)	3.6 (1.0)
MTX + LEF + GC	4 (3.5)	3.1 (1.2)	9 (2.0)	4.3 (1.1)
Other	3 (2.6)	–	21 (4.6)	–

* DAS based on the non-imputed database. csDMARD: conventional synthetic disease-modifying antirheumatic drugs; MTX: methotrexate; SSZ: sulfasalazine; HCQ: hydroxychloroquine; LEF: leflunomide; GC: glucocorticoid; DAS: Disease Activity Score.

stratification for sex, differences in improvement in DAS over time proved to be negligible between men (β -0.69 , 95% CI -0.75 to -0.62 per yr) and women (β -0.58 , 95% CI -0.62 to -0.55 per yr), and the change in HAQ over time was not different between men and women ($p = 0.200$; Table 3).

When analyses were repeated in the subgroups of the different medication strategies, the interaction term between sex and time was statistically significant for the DAS outcome over time only in the csDMARD combination therapy subgroup ($p = 0.014$), but analyses stratified for sex revealed no clinically relevant differences in improvement in DAS over time (β -0.89 , 95% CI -1.07 to -0.71) for men and (β -0.59 , 95% CI -0.67 to -0.51 for women per yr; Table 3). For all other treatment strategies, there were no differences in DAS and HAQ improvement between men and women. Detailed outcomes for the subgroup analyses on the effect of sex on treatment response are shown in Supplementary Tables 10 and 11 (available with the online version of this article). When subanalyses were performed within the strategy subgroups for individual medication combinations, there were no sex differences in treatment response as

measured by DAS and HAQ (Supplementary Table 12, available with the online version of this article).

DISCUSSION

In our study based on real-world clinical data, we aimed to assess whether men and women with RA are treated differently and whether the response to various therapies differs between them. Previously, a concern has been raised that women with RA might be treated less aggressively than men. For instance, a study in the NOR-DMARD registry reported lower access to biologic (b-) DMARD for females in the period 2000–2003 but not in more recent periods (2009–2011)¹⁷. Another study in the QUEST-RA database found no significant differences in the proportion of men and women taking prednisone, MTX, or bDMARD and showed similar delays of initiation to therapy⁷. In our current study, we found that women had, at the start of treatment, slightly longer symptom duration than men, and more often started treatment with HCQ as monotherapy (women 33% vs men 19%), in combination with MTX (58% vs 41%), or with a GC (15% vs 8%), whereas men more often started treatment

Table 3. Evolution of HAQ and DAS over time in men and women^a.

Variables	HAQ	DAS		p ^b
	p ^b	Men, β (95% CI)	Women, β (95% CI)	
All patients, n		1142	4393	
Sex and followup time interaction	0.200	–	–	0.011
Followup time, yrs		–0.69 (–0.75 to –0.62)	–0.58 (–0.62 to –0.55)	
csDMARD combination therapy, n		233	947	
Sex and followup time interaction	0.706	–	–	0.014
Followup time, yrs		–0.89 (–1.07 to –0.71)	–0.59 (–0.67 to –0.51)	
csDMARD monotherapy, n		421	1804	
Sex and followup time interaction	0.453	–	–	0.178
GC, n		103	252	
Sex and followup time interaction	0.283	–	–	0.462
csDMARD + GC, n		271	928	
Sex and followup time interaction	0.419	–	–	0.263
csDMARD combination + GC, n		114	452	
Sex and followup time interaction	0.848	–	–	0.931

^a Results stem from linear multivariable mixed model analyses adjusted for age, RF, ACPA, symptom duration at diagnosis, BMI, smoking, and country. Different models were constructed for all patients and then for treatment subgroups. Regression coefficients represent the units of change in the outcome per unit of time, in this case, per year. ^b P values are shown only for the interactions between sex and time. In the presence of a statistically significant interaction, results are stratified by sex, and the evolution of DAS over time is shown for men and women separately. HAQ: Health Assessment Questionnaire; DAS: Disease Activity Score; csDMARD: conventional synthetic disease-modifying antirheumatic drugs; GC: glucocorticoids; RF: rheumatoid factor; ACPA: anticitrullinated protein antibodies; BMI: body mass index.

with MTX and/or SSZ. This indeed suggests a slightly less aggressive approach in women compared to men: HCQ monotherapy reportedly has only a small effect in reducing the swollen joint count, and its effects on delaying joint damage are smaller compared to SSZ^{18,19}. We found that HCQ was prescribed to male patients mostly if they had low disease activity, but women were treated with HCQ or other csDMARD irrespective of disease activity. It has to be said, though, that sex differences in medication use were slightly country-dependent. This could be influenced by political, economic, or cultural factors that might differ per country but fall beyond the scope of this article.

We found a slightly worse response to treatment for women than for men, but the difference was small (decrease in DAS, when extrapolated to a year, differed by 0.1 point), and appeared to be based on a statistically significant difference in DAS improvement only for initial treatment with csDMARD combination therapy. Also, this difference between men and women was, in clinical terms, negligible.

It could be argued that women more often receive HCQ because HCQ is considered safe during pregnancy, in contrast to, for example, MTX, and might therefore be prescribed to pregnant women or to women with a desire to conceive²⁰. It was indeed observed that women ≤ 50 years of age more often received HCQ; however, this effect was the same for men and therefore does not seem to be related to (wish for) pregnancy. Moreover, we assessed whether age (< 50 yrs or ≥ 50 yrs) was an effect modifier for the association between

sex and treatment response, but we did not find a different response to treatment for these different age categories.

Previous studies in different registers have reported higher response rates in men compared to women for several treatment strategies with bDMARD^{8,9,21}. However, the selection of patients in these studies differs from our current study, in which initial treatment in newly diagnosed patients with RA were compared. An analysis in the BeSt study, a randomized clinical trial, identified male sex as a predictor of MTX efficacy, which we did not find in our current study²². This might be due to differences in patient selection, such as a DAS 1 point higher at baseline in the BeSt study, or to differences in, for example, dosing schedules in a trial setting compared to daily clinical practice.

It has been suggested that a higher level of disease activity in women is inherent to the components of disease activity composite scores, rather than to differences in specifically rheumatic activity in men and women⁷. For example, erythrocyte sedimentation rate levels are usually higher in women than in men, especially in older women^{7,23}, and women often report more symptoms and pain in questionnaires compared to men^{1,7}. In addition, men may have a tendency to underreport problems, as has been described with regard to the HAQ²⁴. This may explain part of the previously found sex differences in response to treatment.

We also found that women had a shorter time to switch medication than men. However, after adjusting for several confounders including disease activity over time, sex no longer determined the likelihood to switch medication.

Our study has several potential limitations. We compared different treatment combinations but did not take into account differences in dosing schedules between patients. Although dosing schedules for many drugs are fixed, this may still influence outcomes. Moreover, because this is an observational study, associations between variables should not be interpreted in a causal manner. Further, because the prescription of medication is not randomized, several known and unknown variables may have influenced the choice of the physician to prescribe certain medication (confounding by indication). Confounding by indication may also have influenced the response to treatment. Because only part of the potential confounders is known and measured, it is always possible that residual (unmeasured) confounding exists.

Our study shows that men and women are prescribed different treatments: women more often started HCQ, as monotherapy or in combination with MTX or a GC, whereas men more often started treatment with MTX and/or SSZ. Although we found a statistically significantly worse response to treatment with csDMARD combination therapy (decrease in DAS but not HAQ) in women compared to men, these differences between the sexes were clinically negligible. In general, although the initial treatments prescribed to men and women may differ, it appears that the clinical response is similar for both sexes.

ONLINE SUPPLEMENT

Supplementary material accompanies the online version of this article.

REFERENCES

- Sherrer YS, Bloch DA, Mitchell DM, Roth SH, Wolfe F, Fries JF. Disability in rheumatoid arthritis: comparison of prognostic factors across three populations. *J Rheumatol* 1987;14:705-9.
- Jawaheer D, Lum RF, Gregersen PK, Criswell LA. Influence of male sex on disease phenotype in familial rheumatoid arthritis. *Arthritis Rheum* 2006;54:3087-94.
- Da Silva JA, Larbre JP, Spector TD, Perry LA, Scott DL, Willoughby DA. Protective effect of androgens against inflammation induced cartilage degradation in male rodents. *Ann Rheum Dis* 1993;52:285-91.
- Ishizuka M, Hatori M, Suzuki T, Miki Y, Darnel AD, Tazawa C, et al. Sex steroid receptors in rheumatoid arthritis. *ClinSci* 2004;106:293-300.
- Kuiper S, van Gestel AM, Swinkels HL, de Boo TM, Da Silva JA, van Riel PL. Influence of sex, age, and menopausal state on the course of early rheumatoid arthritis. *J Rheumatol* 2001;28:1809-16.
- Wilder RL. Adrenal and gonadal steroid hormone deficiency in the etiopathogenesis of rheumatoid arthritis. *J Rheumatol Suppl.* 1996 Jul;44:10-2.
- Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, et al; QUEST-RA Group. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. *Arthritis Res Ther* 2009;11:R7.
- Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. *Rheumatology* 2006;45:1558-65.
- Jawaheer D, Olsen J, Hetland ML. Sex differences in response to anti-tumor necrosis factor therapy in early and established rheumatoid arthritis — results from the DANBIO registry. *J Rheumatol* 2012;39:46-53.
- Asikainen J, Nikiphorou E, Kaarela K, Lindqvist E, Hakkinen A, Kautiainen H, et al. Is long-term radiographic joint damage different between men and women? Prospective longitudinal data analysis of four early RA cohorts with greater than 15 years follow-up. *Clin Exp Rheumatol* 2016;34:641-5.
- Forslund K, Hafstrom I, Ahlmen M, Svensson B; BARFOT Study Group. Sex: a major predictor of remission in early rheumatoid arthritis? *Ann Rheum Dis* 2007;66:46-52.
- Hallert E, Thyberg I, Hass U, Skargren E, Skogh T. Comparison between women and men with recent onset rheumatoid arthritis of disease activity and functional ability over two years (the TIRA project). *Ann Rheum Dis* 2003;62:667-70.
- Bergstra SA, Machado PM, van den Berg R, Landewe RB, Huizinga TW. Ten years of METEOR (an international rheumatoid arthritis registry): development, research opportunities and future perspectives. *Clin Exp Rheumatol* 2016;5 Suppl 101:S87-90.
- van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. *Ann Rheum Dis* 1990;49:916-20.
- Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. *Arthritis Rheum* 1980;23:137-45.
- Schafer JL. Analysis of incomplete multivariate data. Boca Raton: Chapman & Hall/CRC; 1997.
- Putrik P, Ramiro S, Lie E, Keszei AP, Kvien TK, van der Heijde D, et al. Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD. *Rheumatology* 2016;55:1217-24.
- Faarvang KL, Egsmose C, Kryger P, Podenphant J, Ingeman-Nielsen M, Hansen TM. Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial. *Ann Rheum Dis* 1993;52:711-5.
- van der Heijde DM, van Riel PL, Nuvér-Zwart IH, van de Putte LB. Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up. *Lancet* 1990;335:539.
- Gerosa M, Schioppo T, Meroni PL. Challenges and treatment options for rheumatoid arthritis during pregnancy. *Expert Opin Pharmacother* 2016;17:1539-47.
- Couderc M, Gottenberg JE, Mariette X, Pereira B, Bardin T, Cantagrel A, et al; Club Rhumatismes et Inflammations. Influence of gender on response to rituximab in patients with rheumatoid arthritis: results from the Autoimmunity and Rituximab registry. *Rheumatology* 2014;53:1788-93.
- Wessels JA, van der Kooij SM, le Cessie S, Kievit W, Barerra P, Allaart CF, et al; Pharmacogenetics Collaborative Research Group. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. *Arthritis Rheum* 2007;56:1765-75.
- Miller A, Green M, Robinson D. Simple rule for calculating normal erythrocyte sedimentation rate. *Br Med J* 1983;286:266.
- van den Ende CH, Breedveld FC, Dijkmans BA, Hazes JM. The limited value of the Health Assessment Questionnaire as an outcome measure in short term exercise trials. *J Rheumatol* 1997;24:1972-7.